Most clinical genetic tests are unable to accurately detect HR deficiency, according to the release, which can be treated with PARP inhibitors, a type of medication used most commonly to treat breast cancer patients with BRCA mutations.
“We suspect there are many more patients without BRCA mutations who could benefit from PARP inhibitors, but doctors do not know which ones they are. Our approach could help close that gap,” Peter Park, PhD, professor of biomedical informatics at HMS’s Blavatnik Institute, said in a statement.
In tests, the new algorithm, called SigMA, correctly identified 74 percent of cell samples with HR deficiency, compared to other screening systems that typically identify HR-deficient cancer cells with only 30 to 40 percent accuracy.
“Pinpointing actionable genetic biomarkers and treating patients with drugs that specifically target the relevant cancer-driving pathways is at the heart of precision medicine. We believe our algorithm can greatly enhance physicians’ ability to deliver such individualized therapy,” Dr. Park said.
More articles on artificial intelligence:
Approving AI for medical use: 7 things to know
Google quietly disbands another AI advisory board
Partners HealthCare pledges to make AI tools accessible to clinicians, researchers
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
